REG - Scancell Hlds - Second Commercial License Agreement with Genmab

Scancell HoldingsAnnouncement

04/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241204:nRSD6884Oa&default-theme=true

RNS Number : 6884O  Scancell Holdings Plc  04 December 2024

4 December 2024

 

Scancell Holdings plc

("Scancell" or the "Company")

 

 

Scancell Announces Genmab Exercises Option to a Second Commercial License
Agreement

 

Following on from a period of exclusive evaluation announced in June 2024,
Genmab has exercised its option to license an anti-glycan monoclonal antibody
generated via Scancell's proprietary

GlyMab® platform

 

This is the second commercial license with Genmab where Genmab has been
granted worldwide exclusive rights for the development and commercialisation
of novel therapeutic products for an antibody from the Scancell Glymab®
platform

 

Scancell is to receive an upfront payment and potential development,
regulatory- and commercial milestone payments of up to a maximum of $630
million if Genmab develops and commercialises products across all defined
modalities. Scancell will also receive low single-digit royalties from Genmab
on net sales of all such commercialised products

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer, today announces that Genmab (NASDAQ: GMAB), an
international biotechnology company, has exercised its option to license a
Scancell investigational anti-glycan monoclonal antibody whereby Genmab has
the exclusive right to develop and commercialise the Scancell antibody in
multiple novel therapeutic products.   Scancell will be eligible to receive
upfront and development and commercialisation milestone payments, as well as
royalties on products sold.

 

The Scancell anti-glycan monoclonal antibody is a humanised antibody developed
by Scancell, using its novel anti-cancer GlyMab® platform. This is one of
five monoclonal antibodies currently in Scancell's antibody portfolio, which
provides a rich reservoir of potential products for its in-house clinical
development and further deals.

 

Prof Lindy Durrant, Chief Scientific Officer, Scancell, commented: "This
option exercise for another anti-glycan monoclonal antibody from the Glymab®
platform builds on our existing relationship with Genmab. The commercial
license agreement follows an exclusive evaluation period, which further
validates that our Glymab® antibody platform can generate novel,
differentiated, highly tumour specific antibodies for therapeutic development.
We are positive about continuing to work with Genmab and providing further
updates to the market on both agreements as they progress."

 

This is the second commercial licence agreement Scancell has signed with
Genmab following an earlier agreement signed in October 2022.

 

-ENDS-

 

 For further information, please contact:
 Scancell Holdings plc                                                    +44 (0) 20 3709 5700
 Phil L'Huillier, CEO

 Professor Lindy Durrant, CSO

 Dr Jean-Michel Cosséry, Non-Executive Chairman

 Panmure Liberum Limited (Nominated Advisor and Joint Broker)             +44 (0) 20 7886 2500
 Emma Earl, Freddy Crossley, Will Goode, Mark Rogers (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 WG Partners LLP (Joint Broker)                                           +44 (0) 20 3705 9330
 David Wilson/Claes Spang/Satheesh Nadarajah/Erland Sternby

 ICR Healthcare
 Mary-Jane Elliott/ Angela Gray/ Lindsey Neville                          +44 (0) 20 37095700

                                                                          scancell@icrhealthcare.com

 
 

 

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer. The Company is building a pipeline of innovative products by utilising
its four technology platforms: Moditope® and ImmunoBody® for vaccines and
GlyMab® and AvidiMab® for antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs.
The Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope® and
ImmunoBody® ) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that are added
onto proteins and / or lipids (GlyMab® ) or enhances the potency of
antibodies and their ability to directly kill tumour cells (AvidiMab® ).

 

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

 

About GlyMab®

Scancell is building a pipeline of differentiated anti-cancer monoclonal
antibodies ('mAbs') that target sugar motifs rather than proteins. The Company
currently has five novel mAbs in early-stage development and has the potential
to use its unique methodology to identify many more mAbs against glycan
targets in the future. All cells are covered by a dense layer of sugar
structures, called glycans, which change when a normal cell turns into a
cancer cell. These glycan motifs that are associated with tumour malignancies
can be targeted by antibodies such as the Company's GlyMab® portfolio. A
robust portfolio of patents and applications, as well as know-how, surround
the GlyMab® platform and generated drug candidates. The GlyMab® technology
is part of Scancell's antibody portfolio, joining AvidiMab®, a technology
that can be applied to all antibodies (regardless of the technology used to
generate them) enhancing their potency and ability to directly kill tumour
cells. This announcement contains inside information for the purposes of
Article 7 of Regulation (EU) 596/2014 (MAR).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRUOUURSRUURUA